← Leaderboards
Davide Trotti
Massachusetts General Hospital
$10,648,257
Attributed
$13,442,244
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.8M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,442,244 · 10
By mechanism
R01$7,816,835 · 4
RF1$3,560,090 · 1
R21$2,065,319 · 5
Top collaborators
- Ya-Ming Hou3 shared
- Piera Pasinelli2 shared
- Marco Trizzino1 shared
- Yongjie Yang1 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Jeffrey D Rothstein$32,739,978
- Piera Pasinelli$5,993,224
Others in their field
Top investigators on “Amyotrophic Lateral Sclerosis”
- Merit E Cudkowicz · Massachusetts General Hospital$54,029,758
- James Dale Berry · Brigham And Women'S Hospital$37,291,450
- Sabrina Paganoni · Massachusetts General Hospital$36,168,406
- Suma Babu · Massachusetts General Hospital$36,168,406
- Jeffrey D Rothstein · Massachusetts General Hospital$22,909,620
- Teepu Siddique · University Of Chicago$22,641,778
Research focus
Amyotrophic Lateral SclerosisIn VitroCellsMotor NeuronsProteinsLinkSpinal CordLifeMouse ModelLeadMutationPhenotypeMotor Neuron DegenerationPathogenesisMolecularPlayUptakeMediatingReportingNeurotoxicityAlzheimer&AposPathologyFamilial Amyotrophic Lateral SclerosisIn Vivo
Grant awards (34)
Role of the TE-cGAS-STING pathway in C9orf72-ALS/FTD pathogenesis$662,789
R01 · FY2025 · NS · contact PI
Role of the TE-cGAS-STING pathway in C9orf72-ALS/FTD pathogenesis$697,907
R01 · FY2024 · NS · contact PI
A role for extracellular vesicles in neuroinflammation associated to frontotemporal dementia$429,000
R21 · FY2022 · NS · contact PI
Tractable models for C9orf72-linked RAN translation in ALS/FTD$195,000
R21 · FY2019 · NS · contact PI
Exosome-mediated propagation of disease linked poly-dipeptides in C9orf72-FTD/ALS$3,560,090
RF1 · FY2018 · AG · contact PI
Tractable models for C9orf72-linked RAN translation in ALS/FTD$234,000
R21 · FY2018 · NS · contact PI
Tractable models for C9orf72-linked RAN translation in ALS/FTD$5,553
R21 · FY2018 · NS · contact PI
Impairment of the glial glutamate transporter GLT1 in ALS$339,063
R01 · FY2015 · NS · contact PI
Role of ABC efflux transporters in ALS$339,063
R01 · FY2015 · NS · contact PI
Development of a mouse model of C9ORF72 ALS/FTD expressing RAN translated peptide$195,000
R21 · FY2015 · NS · contact PI
Role of ABC efflux transporters in ALS$335,673
R01 · FY2014 · NS · contact PI
Impairment of the glial glutamate transporter GLT1 in ALS$335,671
R01 · FY2014 · NS · contact PI
Development of a mouse model of C9ORF72 ALS/FTD expressing RAN translated peptide$232,750
R21 · FY2014 · NS · contact PI
Impairment of the glial glutamate transporter GLT1 in ALS$327,196
R01 · FY2013 · NS · contact PI
Role of ABC efflux transporters in ALS$327,196
R01 · FY2013 · NS · contact PI
Role of ABC efflux transporters in ALS$339,063
R01 · FY2012 · NS · contact PI
Impairment of the glial glutamate transporter GLT1 in ALS$339,063
R01 · FY2012 · NS · contact PI
Mechanisms of Mutant SOD 1-Mediated Mitochondria Toxicity in the Spinal Cord of A$331,209
R01 · FY2012 · NS · contact PI
Role of ABC efflux transporters in ALS$338,843
R01 · FY2011 · NS · contact PI
Mechanisms of Mutant SOD 1-Mediated Mitochondria Toxicity in the Spinal Cord of A$331,209
R01 · FY2011 · NS · contact PI
Impairment of the glial glutamate transporter GLT1 in ALS$424,875
R01 · FY2010 · NS · contact PI
Mechanisms of Mutant SOD 1-Mediated Mitochondria Toxicity in the Spinal Cord of A$334,590
R01 · FY2010 · NS · contact PI
P-GLYCOPROTEIN MEDIATED CHEMORESISTANCE IN ALS THERAPY$167,294
R21 · FY2010 · NS · contact PI
Impairment of the glial glutamate transporter GLT1 in ALS$424,875
R01 · FY2009 · NS · contact PI
Mechanisms of Mutant SOD 1-Mediated Mitochondria Toxicity in the Spinal Cord of A$337,969
R01 · FY2009 · NS · contact PI
P-GLYCOPROTEIN MEDIATED CHEMORESISTANCE IN ALS THERAPY$202,781
R21 · FY2009 · NS · contact PI
Impairment of Glial Glutamate Transporter GLT1 in ALS$178,290
R01 · FY2006 · NS · contact PI
Impairment of Glial Glutamate Transporter GLT1 in ALS$62,441
R01 · FY2006 · NS · contact PI
Impairment of Glial Glutamate Transporter GLT1 in ALS$246,525
R01 · FY2005 · NS
Impairment of Glial Glutamate Transporter GLT1 in ALS$246,525
R01 · FY2004 · NS
Treatment with Gutamate Uptake Enhancers$204,343
R21 · FY2004 · NS
Impairment of Glial Glutamate Transporter GLT1 in ALS$246,525
R01 · FY2003 · NS
ALS Treatment with Gutamate Uptake Enhancers$199,598
R21 · FY2003 · NS
Impairment of Glial Glutamate Transporter GLT1 in ALS$270,275
R01 · FY2002 · NS